Hong Kong · Delayed Price · Currency is HKD Lepu Biopharma Statistics
Total Valuation
Lepu Biopharma has a market cap or net worth of HKD 7.48 billion. The enterprise value is 7.90 billion.
| Market Cap | 7.48B |
| Enterprise Value | 7.90B |
Important Dates
The next estimated earnings date is Friday, November 20, 2026.
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lepu Biopharma has 1.80 billion shares outstanding. The number of shares has increased by 5.34% in one year.
| Current Share Class | 1.80B |
| Shares Outstanding | 1.80B |
| Shares Change (YoY) | +5.34% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 29.00% |
| Owned by Institutions (%) | 9.82% |
| Float | 938.49M |
Valuation Ratios
The trailing PE ratio is 26.19.
| PE Ratio | 26.19 |
| Forward PE | n/a |
| PS Ratio | 6.54 |
| PB Ratio | 4.67 |
| P/TBV Ratio | 7.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 27.71 |
| EV / Sales | 6.90 |
| EV / EBITDA | 97.89 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.85.
| Current Ratio | 1.14 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.85 |
| Debt / EBITDA | 16.60 |
| Debt / FCF | n/a |
| Interest Coverage | -0.09 |
Financial Efficiency
Return on equity (ROE) is 24.24% and return on invested capital (ROIC) is -0.18%.
| Return on Equity (ROE) | 24.24% |
| Return on Assets (ROA) | -0.07% |
| Return on Invested Capital (ROIC) | -0.18% |
| Return on Capital Employed (ROCE) | -0.15% |
| Weighted Average Cost of Capital (WACC) | 2.14% |
| Revenue Per Employee | 1.77M |
| Profits Per Employee | 441,437 |
| Employee Count | 646 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, Lepu Biopharma has paid 1.94 million in taxes.
| Income Tax | 1.94M |
| Effective Tax Rate | 0.66% |
Stock Price Statistics
The stock price has decreased by -52.49% in the last 52 weeks. The beta is -0.42, so Lepu Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.42 |
| 52-Week Price Change | -52.49% |
| 50-Day Moving Average | 4.38 |
| 200-Day Moving Average | 4.83 |
| Relative Strength Index (RSI) | 41.91 |
| Average Volume (20 Days) | 11,742,440 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lepu Biopharma had revenue of HKD 1.14 billion and earned 285.17 million in profits. Earnings per share was 0.16.
| Revenue | 1.14B |
| Gross Profit | 1.02B |
| Operating Income | -3.77M |
| Pretax Income | 295.67M |
| Net Income | 285.17M |
| EBITDA | 82.12M |
| EBIT | -3.77M |
| Earnings Per Share (EPS) | 0.16 |
Balance Sheet
The company has 910.87 million in cash and 1.36 billion in debt, with a net cash position of -451.97 million or -0.25 per share.
| Cash & Cash Equivalents | 910.87M |
| Total Debt | 1.36B |
| Net Cash | -451.97M |
| Net Cash Per Share | -0.25 |
| Equity (Book Value) | 1.60B |
| Book Value Per Share | 0.90 |
| Working Capital | 167.12M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 86.96M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 88.98%, with operating and profit margins of -0.33% and 24.92%.
| Gross Margin | 88.98% |
| Operating Margin | -0.33% |
| Pretax Margin | 25.83% |
| Profit Margin | 24.92% |
| EBITDA Margin | 7.18% |
| EBIT Margin | -0.33% |
| FCF Margin | n/a |
Dividends & Yields
Lepu Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.34% |
| Shareholder Yield | -5.34% |
| Earnings Yield | 3.81% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Lepu Biopharma has an Altman Z-Score of 2.52 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.52 |
| Piotroski F-Score | 4 |